全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Carotid Atherosclerosis as a Surrogate Maker of Cardiovascular Disease in Diabetic Patients

DOI: 10.1155/2013/979481

Full-Text   Cite this paper   Add to My Lib

Abstract:

Many studies have shown that carotid intima-media thickness (IMT) is associated with cardiovascular disease (CVD). Although it remains inconclusive whether assessment of carotid IMT is useful as a screening test for CVD in Japanese diabetic patients, a total of 271 patients (151 men aged 66 ± 10 (standard deviation) years and 220 women aged 71 ± 8 years) were divided into two groups based on the presence of CVD. We cross-sectionally assessed the ability of carotid IMT to identify CVD corresponding to treatment that was examined by receiver-operating characteristic (ROC) curve analyses. Among the 271 diabetic patients, 199 non-CVD and 72 CVD patients were examined. Multiple linear regression analysis using the presence of CVD as an objective variable showed that carotid IMT ( , ) as well as other confounding factors was a significant independent contributing factor. The ROC curve analysis showed that the best marker of CVD was carotid IMT, with an area under the ROC curve of 0.718 (95% confidence interval (CI), 0.650–0.785). The greatest sensitivity and specificity were obtained when the cut-off value of mean carotid IMT was set at 0.95?mm (sensitivity = 0.71, specificity = 0.60, and accuracy = 0.627). Our study suggests that carotid IMT may be useful for screening diabetic patients with CVD. 1. Introduction Diabetes is associated with a high risk of cardiovascular disease (CVD) which is the most common cause of mortality in people with diabetes. CVD accounts for more than 70% of deaths in people with diabetes [1]. A two- to fourfold increased risk of CVD in people with diabetes compared without diabetes has been reported by various research groups [2–4]. Carotid intima-media thickness (IMT) can now be measured noninvasively by B-mode ultrasonography and is an important and sensitive surrogate marker of cardiovascular disease (CVD). A lot of evidence has shown close associations between this parameter and conventional cardiovascular risk factors, including age, obesity, smoking status, hypertension, and dyslipidemia including hypertriglycerides, low high-density lipoprotein cholesterol (HDL-C) level, increased low-density lipoprotein cholesterol (LDL-C) level, and diabetes [5, 6]. In prospective studies, carotid IMT predicted clinical CVD events independently of traditional risk factors [7–10]. Recent findings have suggested that IMT measurements can be used to stratify patients into high-risk groups [11], but meta-analyses have found that carotid IMT is not predictive of cardiovascular events [12, 13], and in 2010 the American Heart Association and the

References

[1]  M. Laakso, “Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention,” Journal of Internal Medicine, vol. 249, no. 3, pp. 225–235, 2001.
[2]  M. Laakso and S. Lehto, “Epidemiology of macrovascular disease in diabetes,” Diabetes Reviews, vol. 5, no. 4, pp. 294–315, 1997.
[3]  S. M. Haffner, S. Lehto, T. R?nnemaa, K. Py?r?l?, and M. Laakso, “Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction,” New England Journal of Medicine, vol. 339, no. 4, pp. 229–234, 1998.
[4]  A. Juutilainen, S. Lehto, T. R?nnemaa, K. Py?r?l?, and M. Laakso, “Type 2 diabetes as a “coronary heart disease equivalent”: an 18-year prospective population-based study in Finnish subjects,” Diabetes Care, vol. 28, no. 12, pp. 2901–2907, 2005.
[5]  R. Salonen and J. T. Salonen, “Progression of carotid atherosclerosis and its determinants: a population-based ultrasonography study,” Atherosclerosis, vol. 81, no. 1, pp. 33–40, 1990.
[6]  R. Salonen and J. T. Salonen, “Determinants of carotid intima-media thickness: a population-based ultrasonography study in Eastern Finnish men,” Journal of Internal Medicine, vol. 229, no. 3, pp. 225–231, 1991.
[7]  M. W. Lorenz, H. S. Markus, M. L. Bots, M. Rosvall, and M. Sitzer, “Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis,” Circulation, vol. 115, no. 4, pp. 459–467, 2007.
[8]  K. Kitagawa, H. Hougaku, H. Yamagami et al., “Carotid intima-media thickness and risk of cardiovascular events in high-risk patients. Results of the Osaka Follow-Up Study for Carotid Atherosclerosis 2 (OSACA2 Study),” Cerebrovascular Diseases, vol. 24, no. 1, pp. 35–42, 2007.
[9]  J. J. Cao, A. M. Arnold, T. A. Manolio et al., “Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the cardiovascular health study,” Circulation, vol. 116, no. 1, pp. 32–38, 2007.
[10]  D. Baldassarre, M. Amato, L. Pustina et al., “Measurement of carotid artery intima-media thickness in dyslipidemic patients increases the power of traditional risk factors to predict cardiovascular events,” Atherosclerosis, vol. 191, no. 2, pp. 403–408, 2007.
[11]  R. Kawamoto, Y. Oka, H. Tomita, A. Kodama, and N. Ootsuka, “Association between abdominal wall fat index on ultrasonography and carotid atherosclerosis in non-obese men,” Journal of Atherosclerosis and Thrombosis, vol. 12, no. 2, pp. 85–91, 2005.
[12]  P. Costanzo, P. Perrone-Filardi, E. Vassallo et al., “Does carotid intima-media thickness regression predict reduction of cardiovascular events?: a meta-analysis of 41 randomized trials,” Journal of the American College of Cardiology, vol. 56, no. 24, pp. 2006–2020, 2010.
[13]  M. W. Lorenz, J. F. Polak, M. Kavousi et al., “Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data,” The Lancet, vol. 379, no. 9831, pp. 2053–2062, 2012.
[14]  P. Greenland, J. S. Alpert, G. A. Beller et al., “2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of cardiology foundation/American Heart association task force on practice guidelines,” Circulation, vol. 122, no. 25, pp. 2748–2764, 2010.
[15]  E. Imai, M. Horio, T. Watanabe et al., “Prevalence of chronic kidney disease in the Japanese general population,” Clinical and Experimental Nephrology, vol. 13, no. 6, pp. 621–630, 2009.
[16]  J. T. Salonen and R. Salonen, “Ultrasonographically assessed carotid morphology and the risk of coronary heart disease,” Arteriosclerosis and Thrombosis, vol. 11, no. 5, pp. 1245–1249, 1991.
[17]  J. H. Stein, C. E. Korcarz, R. T. Hurst et al., “American Society of Echocardiography Carotid Intima-Media Thickness Task Force; Endorsed by the Society for Vascular Medicine. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force,” Journal of the American Society of Echocardiography, vol. 21, no. 2, pp. 93–111, 2008.
[18]  S. M. Grundy, J. I. Cleeman, S. R. Daniels et al., “Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute scientific statement,” Circulation, vol. 112, no. 17, pp. 2735–2752, 2005.
[19]  Examination Committee of Criteria, “Obesity Disease in Japan; Japan Society for Study of Obesity,New criteria for “obesity disease” in Japan,” Circulation Journal, vol. 66, no. 11, pp. 987–992, 2002.
[20]  T. Ota, T. Takamura, N. Hirai, and K.-I. Kobayashi, “Preobesity in World Health Organization classification involves the metabolic syndrome in Japanese,” Diabetes Care, vol. 25, no. 7, pp. 1252–1253, 2002.
[21]  A. Poli, E. Tremoli, A. Colombo, M. Sirtori, P. Pignoli, and R. Paoletti, “Ultrasonographic measurement of the common carotid artery wall thickness in hypercholesterolemic patients. A new model for the quantitation and follow-up of preclinical atherosclerosis in living human subjects,” Atherosclerosis, vol. 70, no. 3, pp. 253–261, 1988.
[22]  R. Salonen, K. Seppanen, R. Rauramaa, and J. T. Salonen, “Prevalence of carotid atherosclerosis and serum cholesterol levels in eastern Finland,” Arteriosclerosis, vol. 8, no. 6, pp. 788–792, 1988.
[23]  L. Sibal, S. C. Agarwal, and P. D. Home, “Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes,” Diabetes, Metabolic Syndrome and Obesity, vol. 4, pp. 23–24, 2011.
[24]  J. F. Polak, M. Szklo, R. A. Kronmal, et al., “The value of carotid artery plaque and intima-media thickness for incident cardiovascular disease: the multi-ethnic study of atherosclerosis,” Journal of the American Heart Association, vol. 2, no. 2, Article ID e000087, 2013.
[25]  H. M. den Ruijter, S. A. Peters, and K. A. Groenewegen, “Common carotid intima-media thickness does not add to Framingham risk score in individuals with diabetes mellitus: the USE-IMT initiative,” Diabetologia, vol. 56, no. 7, pp. 1494–1502, 2013.
[26]  H. M. den Ruijter, S. A. Peters, T. J. Anderson, et al., “Common carotid intima-media thickness measurements in cardiovascular risk prediction: a Meta-analysis,” Journal of the American Medical Association, vol. 308, no. 8, pp. 796–803, 2012.
[27]  J. F. Polak, M. J. Pencina, A. Meisner et al., “Associations of carotid artery intima-media thickness (IMT) with risk factors and prevalent cardiovascular disease: comparison of mean common carotid artery IMT with maximum internal carotid artery IMT,” Journal of Ultrasound in Medicine, vol. 29, no. 12, pp. 1759–1768, 2010.
[28]  A. Iglesias Del Sol, M. L. Bots, D. E. Grobbee, A. Hofman, and J. C. M. Witteman, “Carotid intima-media thickness at different sites: relation to incident myocardial infarction—the Rotterdam study,” European Heart Journal, vol. 23, no. 12, pp. 934–940, 2002.
[29]  Y. Irie, N. Katakami, H. Kaneto, et al., “The utility of carotid ultrasonography in identifying severe coronary artery disease in asymptomatic type 2 diabetic patients without history of coronary artery disease,” Diabetes Care, vol. 36, no. 5, pp. 1327–1334, 2013.
[30]  R. Kawamoto, K. Kohara, Y. Tabara, T. Miki, and N. Otsuka, “Serum gamma-glutamyl transferase levels are associated with metabolic syndrome in community-dwelling individuals,” Journal of Atherosclerosis and Thrombosis, vol. 16, no. 4, pp. 355–362, 2009.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133